Table 1.
Patient Demographics
| Characteristic | Monitored by CardioMems (N = 26) | Newly Diagnosed (n = 10) | Previously Diagnosed (n = 16) |
|---|---|---|---|
| Age at PAH diagnosis, y | 51.3 ± 18.3 | 55.7 ± 21.7 | 48.6 ± 15.9 |
| Age at study consent, y | 55 ± 18.3 | 55.8 ± 21.7 | 54.6 ± 16.6 |
| Time to implant, d | 15 ± 26.2 | 13.6 ± 27.3 | 16.1 ± 26.5 |
| Female | 24 (92) | 9 (90) | 15 (94) |
| Race | |||
| White | 23 (88) | 8 (80) | 15 (94) |
| Black | 3 (12) | 2 (20) | 1 (6) |
| WHO group 1 PAH subgroup | |||
| Idiopathic | 13 (50) | 6 (60) | 7 (43.8) |
| Heritable | 2 (7.7) | 2 (20) | 0 (0) |
| Drug- and toxin-induced | 3 (11.5) | 0 (0) | 3 (18.8) |
| Associated with CTD | 8 (30.8) | 2 (20) | 6 (37.5) |
| Scleroderma | 6 (23.1) | 1 (18.8) | 5 (31.3) |
| Nonscleroderma | 2 (7.7) | 1 (10) | 1 (6.3) |
| BMI, kg/m2 | 33.9 ± 9.9 | 33.9 ± 11.1 | 33.8 ± 9.5 |
| Heart rate, beats/min | 78.8 ± 13.9 | 74.6 ± 16.9 | 81.4 ± 11.4 |
| 6MWD, m | 266.8 ± 153.8 | 207.1 ± 141.1 | 300.5 ± 154.5 |
| NYHA class | |||
| III | 22 (84.6) | 7 (70) | 15 (93.8) |
| IV | 4 (15.4) | 3 (30) | 1 (6.3) |
| Creatinine, mg/dL | 0.89 ± 0.24 | 0.78 ± 0.14 | 0.95 ± 0.27 |
| REVEAL Registry risk score | 10 ± 1.5 | 10 ± 1.2 | 10 ± 1.8 |
| Baseline BP prior to implant | |||
| Fick cardiac index, L/(min-m2) | 2.5 ± 0.8 | 2 ± 0.6 | 2.8 ± 0.9 |
| Systemic systolic BP, mm Hg | 117.7 ± 17.6 | 118.5 ± 14.3 | 117.1 ± 19.8 |
| Systemic BP, mm Hg | 68.1 ± 10.6 | 70.8 ± 10 | 66.4 ± 10.9 |
| Systolic PAP, mm Hg | 90 ± 18.7 | 90.2 ± 24.3 | 89.8 ± 14 |
| Diastolic PAP, mm Hg | 34.8 ± 8.1 | 37 ± 7.1 | 33.1 ± 8.7 |
| Mean PAP, mm Hg | 56.6 ± 10.5 | 57.3 ± 13.6 | 56.1 ± 8 |
| PA wedge pressure, mm Hg | 10.9 ± 3.6 | 9.3 ± 3.2 | 12.2 ± 3.5 |
| Right atrial pressure, mm Hg | 10.3 ± 4.3 | 10.5 ± 4.8 | 10.1 ± 4.1 |
| Pulmonary vascular resistance, Wood units | 917.1 ± 511.5 | 1162.3 ± 589.3 | 712.8 ± 339.3 |
| PDE5i | 18 (69) | 6 (60) | 12 (75) |
| ERAs | 14 (54) | 3 (30) | 11 (69) |
| Riociguat | 3 (12) | 1 (10) | 2 (13) |
| Parenteral prostacyclins | 18 (69) | 6 (60) | 12 (75) |
| Two of listed drugs | 7 (27) | 4 (40) | 3 (19) |
| Three of listed drugs | 16 (62) | 5 (50) | 11 (69) |
Values are No. (%) or mean ± SD. 6MWD = 6-min walk distance; CTD = connective tissue disease; ERA = endothelin antagonist; NYHA = New York Heart Association; PAH = pulmonary arterial hypertension; PAP = pulmonary arterial pressure; PDE5i = phosphodiesterase type 5 inhibitor; WHO = World Health Organization.